Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

SAGE Therapeutics skyrockets as second depression drug in as many months aces mid-stage trial

Sage’s SAGE-217 drug was statistically significant in reducing the symptoms of major depressive disorder compared to a placebo
depressed woman
The company looks set to add the best of US$2.5bn to its market value on the back of the results

Shares in SAGE Therapeutics Inc (NASDAQ:SAGE) skyrocketed in premarket trading on Thursday after the biotech’s depression drug aced a mid-stage trial.

In a statement, the Massachusetts-based group said 64% of patients taking its SAGE-217 drug saw their major depressive disorder (MDD) go into remission within 15 days of treatment.

Patients were assessed on a scale that rated the severity of their depression symptoms such as mood, feelings of guilt, suicidal thoughts and insomnia.

Shares gained 79.9% to US$165.30 in premarket trade on Thursday, leaving the firm on course to add around US$2.5bn to its market value.

“These very encouraging data suggest the potential of SAGE-217 in the treatment of MDD as well as other mood-related disorders that we may pursue,” said Jeff Jonas, Sage’s chief executive.

“The positive activity and safety findings of SAGE-217 in MDD support advancing the program into later stage clinical development and we will work with the FDA to determine next steps in the further development of SAGE-217.”

It’s Sage’s second success in as many months. Back in November the company said its brexanolone postpartum depression drug met its main goal in two late-stage studies, pacing the way for the first FDA-approved treatment for the disorder.

According to Reuters, Sage won’t seek to partner with another company for the phase III trial.

In the regular session, shares added over 76% to US$162.22 each.

View full SAGE profile View Profile

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use